Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence

Khalid B Beshir, Colin J Sutherland, Patrick Sawa, Chris J Drakeley, Lucy Okell, Collins K Mweresa, Sabah A Omar, Seif A Shekalaghe, Harparkash Kaur, Arnold Ndaro, Jaffu Chilongola, Henk D F H Schallig, Robert W Sauerwein, Rachel L Hallett, Teun Bousema, Khalid B Beshir, Colin J Sutherland, Patrick Sawa, Chris J Drakeley, Lucy Okell, Collins K Mweresa, Sabah A Omar, Seif A Shekalaghe, Harparkash Kaur, Arnold Ndaro, Jaffu Chilongola, Henk D F H Schallig, Robert W Sauerwein, Rachel L Hallett, Teun Bousema

Abstract

Background: Parasite clearance time after artemisinin-based combination therapy (ACT) may be increasing in Asian and African settings. The association between parasite clearance following ACT and transmissibility is currently unknown.

Methods: We determined parasite clearance dynamics by duplex quantitative polymerase chain reaction (qPCR) in samples collected in the first 3 days after treatment of uncomplicated malaria with ACT. Gametocyte carriage was determined by Pfs25 quantitative nucleic acid sequence-based amplification assays; infectiousness to mosquitoes by membrane-feeding assays on day 7 after treatment.

Results: Residual parasitemia was detected by qPCR in 31.8% (95% confidence interval [CI], 24.6-39.8) of the children on day 3 after initiation of treatment. Residual parasitemia was associated with a 2-fold longer duration of gametocyte carriage (P = .0007), a higher likelihood of infecting mosquitoes (relative risk, 1.95; 95% CI, 1.17-3.24; P = .015), and a higher parasite burden in mosquitoes (incidence rate ratio, 2.92; 95% CI, 1.61-5.31; P < .001). Children with residual parasitemia were also significantly more likely to experience microscopically detectable parasitemia during follow-up (relative risk, 11.25; 95% CI, 4.08-31.01; P < .001).

Conclusions: Residual submicroscopic parasitemia is common after ACT and is associated with a higher transmission potential. Residual parasitemia may also have consequences for individual patients because of its higher risk of recurrent parasitemia.

Keywords: PCR; anopheles; artemisinin; infectivity; resistance; submicroscopic; transmission.

Figures

Figure 1.
Figure 1.
Plasmodium falciparum parasite prevalence and relative density by duplex quantitative polymerase chain reaction (qPCR), by treatment arm. Left y-axis, qPCR parasite prevalence (bars) for children treated with artemether-lumefantrine (AL; n = 84) or dihydroartemisinin-piperaquine (DP; n = 70). Error bars indicate the upper limit of the 95% confidence interval. Right y-axis, median relative parasite density relative to starting infection is plotted (line) for PCR-positive individuals treated with AL (solid line) or DP (dashed line). All samples were collected between 10 am and 12 pm (day 0) or between 8 am and 12 pm (days 1, 2, and 3).
Figure 2.
Figure 2.
Plasmodium falciparum gametocyte prevalence by quantitative nucleic acid sequence–based amplification for children whose infection cleared or who had residual parasitemia detected by duplex quantitative polymerase chain reaction on day 3 after treatment with artemether-lumefantrine or dihydroartemisinin-piperaquine. Error bars indicate the upper limit of the 95% confidence interval.

References

    1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.
    1. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.
    1. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6.
    1. Carrara VI, Zwang J, Ashley EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One. 2009;4:e4551.
    1. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis. 2008;14:716–9.
    1. Denis MB, Tsuyuoka R, Lim P, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006;11:1800–7.
    1. Denis MB, Tsuyuoka R, Poravuth Y, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006;11:1360–6.
    1. White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330–4.
    1. Borrmann S, Sasi P, Mwai L, et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One. 2011;6:e26005.
    1. White NJ. The parasite clearance curve. Malar J. 2011;10:278.
    1. Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851–8.
    1. O'Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis. 2010;10:545–55.
    1. Barnes KI, Chanda P, Ab Barnabas G. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar J. 2009;8(Suppl 1):S8.
    1. Stepniewska K, Ashley E, Lee SJ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2010;201:570–9.
    1. Beshir KB, Hallett RL, Eziefula AC, et al. Measuring the efficacy of anti-malarial drugs in vivo: quantitative PCR measurement of parasite clearance. Malar J. 2010;9:312.
    1. Sutherland CJ. Comparing highly efficacious antimalarial drugs. PLoS Med. 2008;5:e228.
    1. Bousema T, Dinglasan RR, Morlais I, et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One. 2012;7:e42821.
    1. Sutherland CJ, Alloueche A, Curtis J, et al. Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg. 2002;67:578–85.
    1. Mendez F, Munoz A, Carrasquilla G, et al. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol. 2002;156:230–8.
    1. Bousema JT, Gouagna LC, Meutstege AM, et al. Treatment failure of pyrimethamine-sulphadoxine and induction of P. falciparum gametocytaemia in children in western Kenya. Trop Med Int Health. 2003;8:427–30.
    1. Hallett RL, Sutherland CJ, Alexander N, et al. Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother. 2004;48:3940–3.
    1. Mendez F, Herrera S, Murrain B, et al. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to anopheles mosquitoes. Am J Trop Med Hyg. 2007;77:438–43.
    1. Hallett RL, Dunyo S, Ord R, et al. Chloroquine/sulphadoxine-pyrimethamine for gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials. 2006;1:e15.
    1. Bousema JT, Schneider P, Gouagna LC, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006;193:1151–9.
    1. Sutherland CJ, Ord R, Dunyo S, et al. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med. 2005;2:e92.
    1. Dondorp AM, Fairhurst RM, Slutsker L, et al. The threat of artemisinin-resistant malaria. N Engl J Med. 2011;365:1073–5.
    1. Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol. 2013;29:313–7.
    1. Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis. 2013;207:1637–45.
    1. World Health Organization. Genotyping to identify parasite populations. Geneva: WHO; 2008.
    1. Snounou G, Viriyakosol S, Zhu XP, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315–20.
    1. Baidjoe A, Stone W, Ploemen I, et al. Combined DNA extraction and antibody elution from filter papers for the assessment of malaria transmission intensity in epidemiological studies. Malar J. 2013;12:272.
    1. Bousema T, Okell L, Shekalaghe S, et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar J. 2010;9:136.
    1. Gadalla NB, Adam I, Elzaki SE, et al. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother. 2011;55:5408–11.
    1. Dinko B, Oguike MC, Larbi JA, Bousema T, Sutherland CJ. Persistent detection of Plasmodium falciparum, P. malariae, P. ovale curtisi and P. ovale wallikeri after ACT treatment of asymptomatic Ghanaian school-children. Int J Parasit: Drugs and Drug Resist. 2013;3:45–50.
    1. Adjalley SH, Johnston GL, Li T, et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A. 2011;108:E1214–23.
    1. Fairhurst RM, Nayyar GM, Breman JG, et al. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg. 2012;87:231–41.
    1. Das D, Price RN, Bethell D, Guerin PJ, Stepniewska K. Early parasitological response following artemisinin-containing regimens: a critical review of the literature. Malar J. 2013;12:125.
    1. Mockenhaupt FP, Teun BJ, Eggelte TA, et al. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Trop Med Int Health. 2005;10:901–8.
    1. Schneider P, Bell AS, Sim DG, et al. Virulence, drug sensitivity and transmission success in the rodent malaria, Plasmodium chabaudi. Proc Biol Sci. 2012;279:4677–85.
    1. Price R, Nosten F, Simpson JA, et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg. 1999;60:1019–23.
    1. Mueller I, Schoepflin S, Smith TA, et al. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A. 2012;109:10030–5.
    1. Bousema T, Griffin JT, Sauerwein RW, et al. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012;9:e1001165.
    1. Liljander A, Bejon P, Mwacharo J, et al. Clearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan children. PLoS One. 2011;6:e16940.
    1. Kwiek JJ, Alker AP, Wenink EC, Chaponda M, Kalilani LV, Meshnick SR. Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections. Antimicrob Agents Chemother. 2007;51:521–7.
    1. Greenhouse B, Dokomajilar C, Hubbard A, Rosenthal PJ, Dorsey G. Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. AntimicrobAgents Chemother. 2007;51:3096–103.
    1. Juliano JJ, Ariey F, Sem R, et al. Misclassification of drug failure in Plasmodium falciparum clinical trials in southeast Asia. J Infect Dis. 2009;200:624–8.
    1. Juliano JJ, Gadalla N, Sutherland CJ, Meshnick SR. The perils of PCR: can we accurately ‘correct’ antimalarial trials? Trends Parasitol. 2010;26:119–24.
    1. Koepfli C, Schoepflin S, Bretscher M, et al. How much remains undetected? Probability of molecular detection of human Plasmodia in the field. PLoS One. 2011;6:e19010.
    1. Irion A, Felger I, Abdulla S, et al. Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children. Trop Med Int Health. 1998;3:490–7.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅